{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Number of participants with MRD negativity at CR or better assessed by using the IMWG criteria.","groups":[{"description":"28 day continuous intravenous infusion of AMG 420 200 µg/day followed by a 2 week treatment-free interval, until progressive disease (PD) or relapse as defined by International Myeloma Working Group (IMWG) response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG000","title":"AMG 420 200 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 400 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG001","title":"AMG 420 400 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 600 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG002","title":"AMG 420 600 µg/Day"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set includes all participants who enrolled and received at least 1 dose of AMG 420.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Number of Participants With Minimal Residual Disease (MRD) Negativity Response at CR","type":"SECONDARY","unitOfMeasure":"Participants"}